EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Gastrointestinal and systemic candidosis in immunocompromised mice



Gastrointestinal and systemic candidosis in immunocompromised mice



Journal of Medical and Veterinary Mycology 27(6): 363-380



Oral-intragastric inoculation of 6-day-old outbred Crl:CFW(SW) BR mice with Candida albicans can lead to colonization of the gastrointestinal (GI) tract. We have shown that in the absence of an immunocompromising treatment, Candida is primarily localized in the stomach and intestines of mice at 20 days post-inoculation. Cultures of homogenates of the esophagus of most animals tested, and homogenates of the liver, lungs, spleen and kidneys of all animals tested, proved negative for C. albicans. Previous histological examinations of the GI tract of these colonized, non-immunocompromised mice showed hyphal elements associated with the stratified, squamous epithelium of the stomach in the region of the cardialatrium fold. In this study, mice were immunocompromised by intraperitoneal injection of cyclophosphamide and cortisone acetate 11-14 days after oral-intragastric challenge with C. albicans and then sacrificed 20 days post-challenge. A high density of invasive hyphae was observed in the same, cardial-atrium region of the stomach of these animals. Cultures of the homogenized stomach showed a 100-fold increase in colony forming units (c.f.u.) of C. albicans compared with stomach homogenates of infected but non-immunocompromised controls. In addition, homogenates of the esophagus and selected body organs of most immunocompromised mice examined were positive for C. albicans by plate culture. When the immunocompromising drug treatment was delayed 3-5 weeks after oral-intragastric challenge, proliferation of C. albicans in the stomach and intestines was still evident, although fewer mice showed systemic spread and lower numbers of c.f.u. were recovered from body organ homogenates. Abscesses which contained both C. albicans hyphae and yeast cells were frequently observed in the liver and occasionally in the lungs and kidneys of immunocompromised mice sacrificed 20 days of post-inoculation. The frequent occurrence of abscesses in the liver stimulates a clinical variant of this mycosis, referred to as focal hepatic candidosis, which has been recognized with increasing frequency in immunocompromised patients. We suggest that the animal model described here may be particularly useful both for exploring methods which may prevent dissemination of C. albicans from localized foci of colonization in the GI tract after exposure of the host to immunocompromising drugs, and for testing the efficacy of anti-Candida drugs in clearance of the pathogen from body organs with established fungal abscesses.

(PDF same-day service: $19.90)

Accession: 001842998

Download citation: RISBibTeXText

PMID: 2628558

DOI: 10.1080/02681218980000491



Related references

Gastrointestinal and systemic candidosis in persistently colonized immunocompromised mice. Abstracts of the Annual Meeting of the American Society for Microbiology 89: 476, 1989

Treatment of experimental candidosis with amphotericin B-Intralipid admixtures in immunocompromised mice. Journal of Antimicrobial ChemoTherapy 48(2): 245-251, 2001

Gastrointestinal colonization and systemic dissemination by Candida albicans and Candida tropicalis in intact and immunocompromised mice. Infection and Immunity 60(11): 4907-4914, 1992

The infant mouse as a model for studies of gastrointestinal and systemic candidosis. Proceedings of the eighth congress of the International Society for Human and Animal Mycology, February 8-12-1982, Massey University, Palmerston North, New Zealand: 155-158, 1983

Gastrointestinal candidosis in mice. Mycoses 42(3): 209-210, 1999

Systemic candidosis in beige mice. Journal of Medical and Veterinary Mycology 27(1): 51-55, 1989

Resistance of germfree mice to systemic candidosis. Journal of the Reticuloendothelial Society 29(3): 241-248, 1981

Chemotherapy of chronic mucocutaneous candidosis and systemic candidosis treated by oral ketoconazole. Chemotherapie von Oberflachen , Organ und Systemmykosen I Deutsches Nizoral Symposium: 58-68, 1982

Kidney function in experimental systemic candidosis of mice. Mycoses 31(4): 203-207, 1988

Treatment of gastrointestinal candidosis in predisposed guinea-pigs and in conventional mice with miconazole. Mykosen 21(12): 417-424, 1978

Pathology of systemic candidosis in mice induced by Candida pseudotropicalis. Candida and candidamycosis: 237-240, 1991

Systemic candidosis in silica-treated athymic and euthymic mice. Infection and Immunity 41(3): 902-907, 1983

Efficacy of SSY726 on systemic candidosis and cryptococcosis in neutropenic mice. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36(0): 113, 1996

Influence of the diagnosis and treatment of digestive candidosis on the finding of systemic candidosis at necropsy in patients with acute leukaemia and hypoplastic pancytopenia. Sangre 27(5): 843-848, 1982

Genetically controlled resistance to fungal infections: systemic candidosis in mice. Progress in Leukocyte Biology 3: 409-419, 1985